Authors: Jade Parker, Editor
The US FDA has approved Libtayo® (cemiplimab-rwlc), the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma (CSCC) in the USA.
CSCC is the second most common form of skin cancer and is responsible for an estimated 7000 deaths each year in the USA. It currently accounts for approximately 20% of all skin cancers in the USA, with the number of newly diagnosed cases expected to rise annually. Libtayo is the third anti-PD-1 approved in the USA.